Effects of Angiotensin II on the action potential durations of atrial myocytes in hypertensive rats

Hypertension Research

Volumn 28, Issue 2, 2005, Pages 173-179

  Sonoyama, Kazuhiko ^f   Igawa, Osamu ^f   Miake, Jun Ichiro ^a   Yamamoto, Yasutaka ^a   Sugihara, Shinobu ^f   Sasaki, Nirihito ^a   Shimoyama, Masaki ^f   Hamada, Toshihiro ^f   Taniguchi, Shin Ichi ^f   Yoshida, Akio ^f   Ogino, Kazuhide ^f   Shigemasa, Chiaki ^f   Hoshikawa, Yoshiko ^a   Kurata, Yasutaka ^b   Shiota, Goshi ^a   Narahashi, Toshio ^c   Horiuchi, Masatsugu ^d   Matsubara, Hiroaki ^e   Ninomiya, Haruaki ^f   Hisatome, Ichiro ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b Kanazawa Medical University   (Japan)

^c NORTHWESTERN UNIVERSITY   (United States)

^d EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^f TOTTORI UNIVERSITY   (Japan)

Author keywords

Action potential; Angiotensin II type 1a receptor; Atrial myocytes; CS 866; Spontaneous hypertensive rats

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; INOSITOL TRISPHOSPHATE; PERTUSSIS TOXIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOLIPASE C INHIBITOR; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; HEART ATRIUM; HEART ATRIUM ARRHYTHMIA; HEART MUSCLE CELL; HEART MUSCLE FIBER MEMBRANE STEADY POTENTIAL; HEART MUSCLE POTENTIAL; HEART MUSCLE REFRACTORY PERIOD; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ACTION POTENTIALS; ANGIOTENSIN II; ANIMALS; ENZYME INHIBITORS; HYPERTENSION; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; RADIOIMMUNOASSAY; RATS; RATS, INBRED SHR; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2;

EID: 20844444329     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.28.173     Document Type: Article

References (34)

1. Baker KM, Booz GW, Dostal DE: Cardiac actions of angiotensin II: role of an intracardiac renin-angiotensin system. Annu Rev Physiol 1992; 54: 227-241.
2. Lindpaintner K, Ganten D: The cardiac renin-angiotensin system. An appraisal of present experimental and clinical evidence. Circ Res 1991; 68: 905-921.
3. Baker KM, Aceto JF: Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol 1990; 259: H610-H618.
4. Nicholls MG, Robertson JI: The renin-angiotensin-system in the year 2000. J Hum Hypertens 2000; 10: 649-666.
5. Goette A, Staack T, Rocken C: Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000; 35: 1669-1677.
6. Pederson OD, Bagger H, Kober L, Torop-Pederson C: Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100: 376-380.
7. Van Den Berg MP, Crijns HJ, Van Veldhuisen DJ, Griep N, Dekam PJ, Liek I: Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Card Fail 1995; 1: 355-364.
8. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K: Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101: 2612-2617.
9. Vermes E, Tardif JC, Bourassa MG, et al: Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction. Circulation 2003; 107: 2926-2931.
10. Madrid AH, Bueno MG, Rebollo JM, et al: Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. A prospective and randomized study. Circulation 2002; 106: 331-336.
11. Kannel WB, Wolf PA, Benjamin EJ, Levy D: Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82: 2N-9N.
12. Dahlof B, Hornestam B, Aurup P: Losartan decreases the risk of stroke in hepertensive patients with atrial fibrillation and left ventricular hypertrophy. Eur Heart J 2002; 23: 412.
13. Wachtell K, Lehto M, Hornestam B, et al: Losartan reduces the risk of new-onset atrial fibrillation in hypertensive patients with electrocardiogram left-ventricular hypertrophy: the LIFE study. Eur Heart J 2003; 24: 504.
14. Sadoshima JI, Izumo S: Signal transduction pathway of angiotensin II-induced c-fos gene expression in cardiac myocytes in vitro. Circ Res 1993; 73: 424-438.
15. Bahinski A, Narin AC, Greengard P, Gadsby DC: Chloride conductance regulated by cyclic AMP-dependent protein kinase in cardiac myocytes. Nature 1989; 340: 718-721.
16. + channels by Class 1 antiarrhythmic agents in the ventricular myocytes and the guinea pig papillary muscle. Biochim Biophys Acta 1999; 1418: 320-334.
17. Isenberg G, Klockner U: Calcium tolerant ventricular myocytes prepared by preincubation in a "KB medium." Pflügers Arch 1982; 395: 6-18.
18. Hamil OP, Marty A, Neher E, Sakman B, Sigworth FJ: Improved patch-clap techniques for high-resolution current recording from cells and cell-free membrane patches. Pflügers Arch 1981; 391: 85-100.
19. Tsutsumi Y, Matsubara H, Masaki H, et al: Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999; 104: 925-935.
20. Jia N, Okamoto H, Shimizu T, et al: A newly developed angiotensin II type I receptor antagonist, CS866, promotes regression of cardiac hypertrophy by reducing integrin β1 expression. Hypertens Res 2003; 26: 737-742.
21. Bonnardeaux JL, Regoli D: Action of angiotensin and analogues on the heart. Can J Physiol Pharmacol 1974; 52: 50-60.
22. Chen SA, Chang MS, Chiang BN, Cheng KK, Lin CI: Electromechanical effects of angiotensin in human atrial tissues. J Mol Cell Cardiol 1991; 23: 483-493.
23. 2+ current in sinoaterial node cells of rabbits. Am J Physiol 1995; 268: H1053-H1060.
24. Morita H, Kimura J, Endoh M: Angiotensin II activation of a chloride current in rabbit cardiac myocytes. J Physiol (Lond) 1995; 483: 119-130.
25. 1 angiotensin II receptor antagonist. Basic Res Cardiol 1997; 92: 129-138.
26. Obayashi K, Horie M, Xie LH, et al: Angiotensin II inhibits protein kinase A-dependent chloride conductance in heart via pertussis toxin-sensitive G proteins. Circulation 1997; 95: 197-204.
27. Miura S, Saku K, Karnik SS: Molecular analysis of the structure and function of the angiotensin II type 1 receptor. Hypertens Res 2003; 26: 937-943.
28. Mizuno M, Sada T, Ikeda M, et al: Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 1995; 285: 181-188.
29. Chorvatova A, Gallo-Payet N, Casanova C, Payet MD: Modulation of membrane potential and ionic currents by the AT1 and AT2 receptors of angiotensin II. Cell Signal 1996; 8: 525-532.
30. to in epicardial and endocardial ventricular myocytes from canine heart. Circ Res 2000; 86: 1062-1068.
31. + channels. Circulation 1997; 96: 3129-3135.
32. Komuro I, Kaida T, Shibazaki Y, et al: Stretching cardiac myocytes stimulates protooncogene expression. J Biol Chem 1990; 265: 3595-3598.
33. Kumagai K, Nakashima H, Urata H, et al: Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003; 41: 2197-2204
34. Zou Y, Akazawa H, Qin Y, et al: Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 2004; 6: 499-506.